Nirmatrelvir in combination with ritonavir is an antiviral treatment for mild-to-moderate coronavirus disease 2019 (Covid-19). The efficacy of this treatment in patients who are at standard risk for ...
The oral protease inhibitor nirmatrelvir has shown substantial efficacy in high-risk, unvaccinated patients infected with the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus ...
In a recent study posted to the bioRxiv* preprint server, researchers test three severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals authorized for emergency use by the United ...
Background and Goal: SARS-CoV-2, the virus responsible for the COVID-19 pandemic, remains in circulation. The focus has now shifted to testing and treating ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback